KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) Gross Margin (2018 - 2025)

Historic Gross Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 90.24%.

  • BioNTech SE's Gross Margin rose 46100.0% to 90.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 82.79%, marking a year-over-year decrease of 15200.0%. This contributed to the annual value of 80.32% for FY2024, which is 39700.0% down from last year.
  • Per BioNTech SE's latest filing, its Gross Margin stood at 90.24% for Q3 2025, which was up 46100.0% from 70.71% recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Gross Margin registered a high of 95.71% during Q4 2022, and its lowest value of 2.86% during Q2 2023.
  • Its 5-year average for Gross Margin is 75.72%, with a median of 80.1% in 2021.
  • In the last 5 years, BioNTech SE's Gross Margin plummeted by -732200bps in 2023 and then surged by 506700bps in 2024.
  • Over the past 5 years, BioNTech SE's Gross Margin (Quarter) stood at 89.46% in 2021, then rose by 7bps to 95.71% in 2022, then fell by -8bps to 87.89% in 2023, then dropped by -10bps to 79.54% in 2024, then rose by 13bps to 90.24% in 2025.
  • Its Gross Margin was 90.24% in Q3 2025, compared to 70.71% in Q2 2025 and 54.16% in Q1 2025.